Form 8-K

8-K — JOHNSON & JOHNSON

Accession: 0000200406-26-000146

Filed: 2026-07-15

Period: 2026-07-15

CIK: 0000200406

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — jnj-20260715.htm (Primary)

EX-99.1 (a2026q2exhibit991.htm)

EX-99.2 (a2026q2exhibit992.htm)

GRAPHIC (image_1.jpg)

GRAPHIC (jnjlogo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: jnj-20260715.htm · Sequence: 1

jnj-20260715

0000200406false00002004062026-07-152026-07-150000200406us-gaap:CommonStockMember2026-07-152026-07-150000200406jnj:A1.150NotesDueNovember2028Member2026-07-152026-07-150000200406jnj:A2.700NotesDueFebruary2029Member2026-07-152026-07-150000200406jnj:A3.20NotesDueJune2032Member2026-07-152026-07-150000200406jnj:A3.050NotesDueFebruary2033Member2026-07-152026-07-150000200406jnj:A1.650NotesDueMay2035Member2026-07-152026-07-150000200406jnj:A3.350NotesDueJune2036Member2026-07-152026-07-150000200406jnj:A3.350NotesDueFebruary2037Member2026-07-152026-07-150000200406jnj:A3.550NotesDueJune2044Member2026-07-152026-07-150000200406jnj:A3.600NotesDueFebruary2045Member2026-07-152026-07-150000200406jnj:A3.700NotesDueFebruary2055Member2026-07-152026-07-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

July 15, 2026

Johnson & Johnson

(Exact name of registrant as specified in its charter)

New Jersey

1-3215

22-1024240

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $1.00

JNJ

New York Stock Exchange

1.150% Notes Due November 2028

JNJ28

New York Stock Exchange

2.700% Notes due February 2029

JNJ29B

New York Stock Exchange

3.200% Notes Due June 2032

JNJ32

New York Stock Exchange

3.050% Notes due February 2033

JNJ33B

New York Stock Exchange

1.650% Notes Due May 2035

JNJ35

New York Stock Exchange

3.350% Notes Due June 2036

JNJ36A

New York Stock Exchange

3.350% Notes due February 2037

JNJ37B

New York Stock Exchange

3.550% Notes Due June 2044

JNJ44

New York Stock Exchange

3.600% Notes due February 2045

JNJ45

New York Stock Exchange

3.700% Notes due February 2055

JNJ55

New York Stock Exchange

Item 2.02 Results of operations and financial condition

On July 15, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 28, 2026.

Item 9.01 Financial statements and exhibits

(d) Exhibits.

Exhibit No. Description of Exhibit

99.1

Press Release dated July 15, 2026 for the period ended June 28, 2026

99.2

Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal second quarter and six months

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 15, 2026

JOHNSON & JOHNSON

(Registrant)

By:

/s/ Robert J. Decker, Jr.

Robert J. Decker, Jr.

Controller

(Principal Accounting Officer)

EX-99.1

Filename: a2026q2exhibit991.htm · Sequence: 2

Document

Exhibit 99.1

Media contact:

media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

For immediate release

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

•2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%*

•2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90

•Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint

•Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, CAPLYTA for the prevention of relapse in schizophrenia, and Dual Energy THERMOCOOL SMARTTOUCH SF platform; fortifying future with data from RYBREVANT FASPRO in advanced head and neck cancer, TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma, and OTTAVA in upper abdominal procedures

New Brunswick, N.J. (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”

Overall financial results

($ in Millions, except EPS)

2026

2025

% Change

Reported Sales

$25,310

$23,743

6.6%

Net Earnings

$5,534

$5,537

-0.1%

EPS (diluted)

$2.27

$2.29

-0.9%

Non-GAAP* ($ in Millions, except EPS)

2026

2025

% Change

Operational Sales1,2

5.6%

Adjusted Operational Sales1,3

5.7%

Adjusted Net Earnings1,4

$7,081

$6,699

5.7%

Adjusted EPS (diluted)1,4

$2.90

$2.77

4.7%

Free Cash Flow5,6

~$8,700

$6,214

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

4Excludes intangible amortization expense and special items

5Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

6Second-quarter YTD 2026 is estimated as of July 15, 2026

Note: values may have been rounded

Regional sales results

% Change

($ in Millions)

2026

2025

Reported

Operational1,2

Currency

Adjusted

Operational1,3

U.S.

$14,533

$13,544

7.3%

7.3

7.4

International

10,777

10,199

5.7

3.4

2.3

3.5

Worldwide

$25,310

$23,743

6.6%

5.6

1.0

5.7

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results

% Change

($ in Millions)

2026

2025

Reported

Operational1,2

Currency

Adjusted

Operational1,3

Innovative Medicine

$16,384

$15,202

7.8%

6.8

1.0

6.9

MedTech

8,926

8,541

4.5

3.6

0.9

3.7

Worldwide

$25,310

$23,743

6.6%

5.6

1.0

5.7

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Second-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 6.8%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 760 basis points impact) and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology.

MedTech

MedTech worldwide operational sales grew 3.6%*, with net acquisitions and divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by wound closure products and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

July 2026

April 2026

Adjusted Operational Sales1,2

Change vs. Prior Year / Mid-point

6.2% – 6.8% / 6.5%

5.6% – 6.6% / 6.1%

Operational Sales2 / Mid-point

Change vs. Prior Year / Mid-point

$100.3B – $100.9B / $100.6B

6.5% – 7.1% / 6.8%

$99.7B – $100.7B / $100.2B

5.9% – 6.9% / 6.4%

Estimated Reported Sales3/ Mid-point

Change vs. Prior Year / Mid-point

$100.8B – $101.4B / $101.1B

7.0% – 7.6% / 7.3%

$100.3B – $101.3B / $100.8B

6.5% – 7.5% / 7.0%

Adjusted Operational EPS (Diluted)2,4 / Mid-point

Change vs. Prior Year / Mid-point

$11.50 – $11.65 / $11.58

6.6% – 8.0% / 7.3%

$11.30 – $11.50 / $11.40

4.7% – 6.7% / 5.7%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$11.60 – $11.75 / $11.68

7.5% – 8.9% / 8.2%

$11.45 – $11.65 / $11.55

6.1% – 8.1% / 7.1%

1Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2Non-GAAP financial measure; excludes the impact of translational currency

3Calculated using Euro Average Rate: July 2026 = $1.15 and April 2026 = $1.17 (Illustrative purposes only)

4Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.

Regulatory

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform1

Press Release

CHMP recommendation advances Johnson & Johnson’s TECVAYLI (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

Press Release

FDA approves label expansion, cementing TREMFYA as the only IL‑23 inhibitor proven to help stop further joint damage

Press Release

FDA approves CAPLYTA (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

Press Release

Johnson & Johnson Announces CE Mark Approval for the New ETHICON 4000 Stapler

Press Release

FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Press Release

Data Releases

Johnson & Johnson presents new IMAAVY (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Press Release

New TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Press Release

IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Press Release

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Press Release

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Press Release

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Press Release

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

Press Release

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Press Release

New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

Press Release

Johnson & Johnson study shows TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Press Release

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Press Release

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

Press Release

CAPLYTA (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

Press Release

IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Press Release

Product Launch

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter

Press Release

Other

DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer1

Press Release

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Press Release

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Press Release

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Press Release

DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio

Press Release

DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS

Press Release

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

Press Release

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Press Release

Johnson & Johnson Launches Landmark Head-to-Head Pulsed Field Ablation Trial in Persistent Atrial Fibrillation

Press Release

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Press Release

1Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

Note to investors concerning forward-looking statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

EX-99.2

Filename: a2026q2exhibit992.htm · Sequence: 3

Document

Exhibit 99.2

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) SECOND QUARTER

Percent Change

Sales to customers by geographic area 2026 2025 Total Operations Currency

U.S.

$14,533 13,544 7.3 % 7.3 —

Europe

5,726 5,387 6.3 3.3 3.0

Western Hemisphere excluding U.S.

1,309 1,206 8.5 2.7 5.8

Asia-Pacific, Africa

3,742 3,606 3.8 3.9 (0.1)

International

10,777 10,199 5.7 3.4 2.3

Worldwide

$25,310 23,743 6.6 % 5.6 1.0

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) SIX MONTHS

Percent Change

Sales to customers by geographic area 2026 2025 Total Operations Currency

U.S.

$27,863 25,849 7.8 % 7.8 —

Europe

11,574 10,497 10.3 3.0 7.3

Western Hemisphere excluding U.S.

2,602 2,373 9.6 2.6 7.0

Asia-Pacific, Africa

7,333 6,917 6.0 4.9 1.1

International

21,509 19,787 8.7 3.6 5.1

Worldwide

$49,372 45,636 8.2 % 6.0 2.2

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) SECOND QUARTER

Percent Change

Sales to customers by segment of business 2026 2025 Total Operations Currency

Innovative Medicine

U.S.

$ 9,979 9,161 8.9 % 8.9 —

International

6,405 6,041 6.0 3.6 2.4

16,384 15,202 7.8 6.8 1.0

MedTech

U.S.

4,554 4,383 3.9 3.9 —

International

4,372 4,158 5.2 3.2 2.0

8,926 8,541 4.5 3.6 0.9

U.S.

14,533 13,544 7.3 7.3 —

International

10,777 10,199 5.7 3.4 2.3

Worldwide

$ 25,310 23,743 6.6 % 5.6 1.0

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) SIX MONTHS

Percent Change

Sales to customers by segment of business 2026 2025 Total Operations Currency

Innovative Medicine

U.S.

$ 18,850 17,253 9.3 % 9.3 —

International

12,960 11,822 9.6 3.9 5.7

31,810 29,075 9.4 7.1 2.3

MedTech

U.S.

9,013 8,596 4.8 4.8 —

International

8,549 7,965 7.3 3.2 4.1

17,562 16,561 6.0 4.1 1.9

U.S.

27,863 25,849 7.8 7.8 —

International

21,509 19,787 8.7 3.6 5.1

Worldwide

$ 49,372 45,636 8.2 % 6.0 2.2

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures) SECOND QUARTER

2026 2025 Percent

Increase

(Decrease)

Amount Percent

to Sales Amount Percent

to Sales

Sales to customers $ 25,310 100.0 $ 23,743 100.0 6.6

Cost of products sold 8,051 31.8 7,628 32.1 5.5

Gross Profit 17,259 68.2 16,115 67.9 7.1

Selling, marketing and administrative expenses 6,432 25.4 5,889 24.8 9.2

Research and development expense 3,653 14.4 3,516 14.8 3.9

Interest (income) expense, net 62 0.2 48 0.2

Other (income) expense, net 331 1.3 107 0.5

Restructuring 34 0.2 64 0.3

Earnings before provision for taxes on income 6,747 26.7 6,491 27.3 3.9

Provision for taxes on income 1,213 4.8 954 4.0 27.1

Net earnings $ 5,534 21.9 $ 5,537 23.3 (0.1)

Net earnings per share (Diluted) $ 2.27 $ 2.29 (0.9)

Average shares outstanding (Diluted) 2,440.1 2,419.1

Effective tax rate 18.0 % 14.7 %

Adjusted earnings before provision for taxes and net earnings (1) (A)

Earnings before provision for taxes on income

$ 8,660 34.2 $ 8,188 34.5

5.8

Net earnings

$ 7,081 28.0 $ 6,699 28.2

5.7

Net earnings per share (Diluted)

$ 2.90

$ 2.77

4.7

Effective tax rate

18.2 %

(1) See Reconciliation of Non-GAAP Financial Measures.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures) SIX MONTHS

2026 2025 Percent

Increase

(Decrease)

Amount Percent

to Sales Amount Percent

to Sales

Sales to customers $ 49,372 100.0 $ 45,636 100.0 8.2

Cost of products sold 16,157 32.7 14,985 32.8 7.8

Gross Profit 33,215 67.3 30,651 67.2 8.4

Selling, marketing and administrative expenses 12,466 25.3 11,001 24.1 13.3

Research and development expense 7,180 14.5 6,741 14.8 6.5

In-process research and development impairments 36 0.1 — —

Interest (income) expense, net 105 0.2 (80) (0.2)

Other (income) expense, net 625 1.3 (7,214) (15.8)

Restructuring 66 0.1 81 0.2

Earnings before provision for taxes on income 12,737 25.8 20,122 44.1 (36.7)

Provision for taxes on income 1,968 4.0 3,586 7.9 (45.1)

Net earnings $ 10,769 21.8 $ 16,536 36.2 (34.9)

Net earnings per share (Diluted) $ 4.41 $ 6.82 (35.3)

Average shares outstanding (Diluted) 2,443.9 2,423.3

Effective tax rate 15.5 % 17.8 %

Adjusted earnings before provision for taxes and net earnings (1) (A)

Earnings before provision for taxes on income

$ 16,481 33.4 $ 16,199 35.5

1.7

Net earnings

$ 13,695 27.7 $ 13,405 29.4

2.2

Net earnings per share (Diluted)

$ 5.60

$ 5.53

1.3

Effective tax rate

16.9 %

17.2 %

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

SECOND QUARTER SIX MONTHS

(Dollars in Millions Except Per Share Data) 2026 2025 2026 2025

Net Earnings, after tax- as reported $5,534 $5,537 $10,769 $16,536

Pre-tax Adjustments

Litigation related 267 57 597 (6,909)

Intangible Asset Amortization expense 1,245 1,267 2,492 2,387

Restructuring related 1

276 79 338 134

Orthopaedics separation related 258 — 377 —

Acquisition, integration and divestiture related 80 246 176 378

(Gains)/losses on securities (213) 21 (272) 60

IPR&D impairments — — 36 —

Other — 27 — 27

Tax Adjustments

Tax impact on special item adjustments 2

(368) (321) (792) 994

Tax legislation and other tax related 2 (214) (26) (202)

Adjusted Net Earnings , after tax $7,081 $6,699 $13,695 $13,405

Average shares outstanding (Diluted) 2,440.1 2,419.1 2,443.9 2,423.3

Adjusted net earnings per share (Diluted) $2.90 $2.77 $5.60 $5.53

Operational adjusted net earnings per share (Diluted) $2.86 $5.43

Notes:

1In the fiscal second quarter of 2026, the Company commenced a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of 2026.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $59 million were recorded in the fiscal second quarter of 2026 ($114 million Q2 2026 YTD) and $29 million in the fiscal second quarter of 2025 ($29 million Q2 2025 YTD) and primarily include costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $17 million in the fiscal second quarter of 2026 ($24 million Q2 2026 YTD) and $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.

2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Second quarter 2026 actual vs. 2025 actual

Segments

Innovative Medicine MedTech Total

WW As Reported 7.8 % 4.5 % 6.6 %

U.S. 8.9 % 3.9 % 7.3 %

International 6.0 % 5.2 % 5.7 %

WW Currency 1.0 0.9 1.0

U.S. — — —

International 2.4 2.0 2.3

WW Operational 6.8 % 3.6 % 5.6 %

U.S. 8.9 % 3.9 % 7.3 %

International 3.6 % 3.2 % 3.4 %

All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1

U.S. 0.0 0.2 0.1

International 0.2 0.0 0.1

WW Adjusted Operational Ex A&D 6.9 % 3.7 % 5.7 %

U.S. 8.9 % 4.1 % 7.4 %

International 3.8 % 3.2 % 3.5 %

Note: Percentages are based on actual, non-rounded figures and may not sum

(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Six months 2026 actual vs. 2025 actual

Segments

Innovative Medicine MedTech Total

WW As Reported 9.4 % 6.0 % 8.2 %

U.S. 9.3 % 4.8 % 7.8 %

International 9.6 % 7.3 % 8.7 %

WW Currency 2.3 1.9 2.2

U.S. — — —

International 5.7 4.1 5.1

WW Operational 7.1 % 4.1 % 6.0 %

U.S. 9.3 % 4.8 % 7.8 %

International 3.9 % 3.2 % 3.6 %

Caplyta (0.9) (0.6)

U.S. (1.6) (1.0)

International 0.0 0.0

All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1

U.S. 0.0 0.2 0.1

International 0.2 0.0 0.1

WW Adjusted Operational Ex A&D 6.2 % 4.2 % 5.5 %

U.S. 7.7 % 5.0 % 6.9 %

International 4.1 % 3.2 % 3.7 %

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson

Segment sales

(Dollars in Millions)

SECOND QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)

ONCOLOGY

US $ 4,069 3,385 20.3 % 20.3 % — %

Intl 3,337 2,928 14.0 11.2 2.8

WW 7,406 6,312 17.3 16.1 1.2

DARZALEX

US 2,435 2,017

20.7 20.7 —

Intl 1,772 1,521

16.4 13.5 2.9

WW 4,207 3,539

18.9 17.6 1.3

CARVYKTI

US 472 358 31.7 31.7 —

Intl 185 81 * * *

WW 657 439 49.4 47.7 1.7

TECVAYLI

US 186 114 63.9 63.9 —

Intl 74 52 40.7 39.2 1.5

WW 260 166 56.5 56.1 0.4

TALVEY

US 112 82 36.2 36.2 —

Intl 62 24 * * *

WW 174 106 63.3 62.6 0.7

RYBREVANT / LAZCLUZE

US 190 139 36.8 36.8 —

Intl 99 41 * * *

WW 289 179 60.8 61.6 (0.8)

ERLEADA

US 396 378 4.7 4.7 —

Intl 599 530 12.9 9.7 3.2

WW 995 908 9.5 7.6 1.9

IMBRUVICA

US 149 239 (37.6) (37.6) —

Intl 449 496 (9.5) (11.8) 2.3

WW 599 735 (18.6) (20.2) 1.6

OTHER ONCOLOGY(3)

US 131 56 * * —

Intl 97 181 (46.5) (45.7) (0.8)

WW 226 238 (4.6) (3.9) (0.7)

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SECOND QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

IMMUNOLOGY

US $ 2,372 2,505 (5.3) % (5.3) % — %

Intl 1,473 1,489 (1.0) (3.5) 2.5

WW 3,844 3,993 (3.7) (4.6) 0.9

TREMFYA

US 1,465 796 84.2 84.2 —

Intl 581 391 48.7 44.2 4.5

WW 2,046 1,186 72.5 71.0 1.5

SIMPONI / SIMPONI ARIA

US 260 305 (14.6) (14.6) —

Intl 358 387 (7.3) (9.5) 2.2

WW 618 690 (10.5) (11.7) 1.2

REMICADE

US 215 283 (24.1) (24.1) —

US Exports(4)

10 34 (71.0) (71.0) —

Intl 112 138 (18.4) (20.5) 2.1

WW 338 455 (25.8) (26.4) 0.6

STELARA

US 336 1,078 (68.8) (68.8) —

Intl 404 575 (29.7) (31.1) 1.4

WW 740 1,653 (55.2) (55.7) 0.5

OTHER IMMUNOLOGY

US 85 8 * * —

Intl 18 0 * * *

WW 104 8 * * *

NEUROSCIENCE

US 1,659 1,377 20.5 20.5 —

Intl 678 674 0.6 (1.1) 1.7

WW 2,337 2,051 14.0 13.4 0.6

SPRAVATO

US 514 366 40.7 40.7 —

Intl 70 50 41.2 34.7 6.5

WW 584 414 40.8 40.0 0.8

CAPLYTA

US 361 211 70.9 70.9 —

Intl — — — — —

WW 361 211 70.9 70.9 —

INVEGA SUSTENNA / XEPLION / INVEGA

TRINZA / TREVICTA

US 738 732 0.8 0.8 —

Intl 278 260 6.6 5.1 1.5

WW 1,015 992 2.3 1.9 0.4

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SECOND QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CONCERTA / methylphenidate

US $ 12 24 (48.6) % (48.6) % — %

Intl 133 139 (4.2) (4.8) 0.6

WW 146 164 (10.8) (11.3) 0.5

OTHER NEUROSCIENCE

US 34 45 (22.9) (22.9) —

Intl 198 226 (12.3) (13.7) 1.4

WW 232 270 (14.0) (15.2) 1.2

PULMONARY HYPERTENSION (PH)

US 814 799 1.8 1.8 —

Intl 329 314 4.9 3.4 1.5

WW 1,143 1,113 2.6 2.2 0.4

UPTRAVI

US 386 382 1.0 1.0 —

Intl 108 94 15.0 10.1 4.9

WW 494 476 3.8 2.8 1.0

OPSUMIT / OPSYNVI

US 416 403 3.2 3.2 —

Intl 187 180 3.9 3.6 0.3

WW 602 582 3.4 3.3 0.1

OTHER PULMONARY HYPERTENSION

US 13 16 (16.9) (16.9) —

Intl 34 40 (14.3) (12.7) (1.6)

WW 47 55 (15.0) (13.9) (1.1)

INFECTIOUS DISEASES (ID)

US 300 320 (6.3) (6.3) —

Intl 463 484 (4.1) (6.2) 2.1

WW 763 803 (5.0) (6.3) 1.3

EDURANT / rilpivirine

US 3 6 (49.6) (49.6) —

Intl 347 354 (1.9) (3.8) 1.9

WW 350 360 (2.7) (4.6) 1.9

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US 296 312 (5.1) (5.1) —

Intl 76 85 (10.4) (12.8) 2.4

WW 372 396 (6.3) (6.8) 0.5

OTHER INFECTIOUS DISEASES

US 1 2 (47.9) (47.9) —

Intl 40 45 (9.6) (12.8) 3.2

WW 41 47 (11.6) (14.6) 3.0

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SECOND QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CARDIOVASCULAR / METABOLISM / OTHER (CVM)

US $ 765 776 (1.3) % (1.3) % — %

Intl 124 154 (19.4) (21.5) 2.1

WW 889 930 (4.3) (4.7) 0.4

XARELTO

US 664 621 7.1 7.1 —

Intl — — — — —

WW 664 621 7.1 7.1 —

OTHER

US 101 155 (35.0) (35.0) —

Intl 124 154 (19.4) (21.5) 2.1

WW 225 309 (27.2) (28.3) 1.1

TOTAL PH, ID, CVM

US 1,878 1,895 (0.9) (0.9) —

Intl 916 952 (3.6) (5.5) 1.9

WW 2,795 2,846 (1.8) (2.4) 0.6

TOTAL INNOVATIVE MEDICINE

US 9,979 9,161 8.9 8.9 —

Intl 6,405 6,041 6.0 3.6 2.4

WW $16,384 15,202 7.8 % 6.8 % 1.0 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SECOND QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)

CARDIOVASCULAR

US $ 1,426 1,364 4.5 % 4.5 % — %

Intl 978 948 3.2 1.1 2.1

WW 2,404 2,313 4.0 3.1 0.9

ELECTROPHYSIOLOGY

US 783 741 5.8 5.8 —

Intl 749 728 2.9 0.4 2.5

WW 1,533 1,468 4.4 3.1 1.3

ABIOMED

US 342 360 (4.8) (4.8) —

Intl 97 89 9.5 9.2 0.3

WW 440 448 (2.0) (2.0) 0.0

SHOCKWAVE

US 268 233 14.6 14.6 —

Intl 67 58 14.5 15.4 (0.9)

WW 335 292 14.6 14.7 (0.1)

OTHER CARDIOVASCULAR

US 33 31 5.5 5.5 —

Intl 65 72 (10.5) (13.2) 2.7

WW 98 104 (5.7) (7.5) 1.8

SURGERY

US 1,094 1,043 5.0 5.0 —

Intl 1,559 1,512 3.1 0.5 2.6

WW 2,653 2,555 3.9 2.3 1.6

ADVANCED

US 499 477 4.7 4.7 —

Intl 691 687 0.5 (1.9) 2.4

WW 1,189 1,164 2.2 0.8 1.4

GENERAL

US 596 567 5.2 5.2 —

Intl 868 825 5.3 2.5 2.8

WW 1,464 1,391 5.2 3.6 1.6

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SECOND QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)(Continued)

VISION

US $565 557 1.4 % 1.4 % — %

Intl 887 813 9.1 8.5 0.6

WW 1,451 1,369 6.0 5.6 0.4

CONTACT LENSES / OTHER

US 445 429 3.6 3.6 —

Intl 580 536 8.1 7.9 0.2

WW 1,025 965 6.1 6.0 0.1

SURGICAL

US 120 128 (6.0) (6.0) —

Intl 306 277 10.9 9.6 1.3

WW 426 403 5.6 4.7 0.9

ORTHOPAEDICS

US 1,470 1,420 3.5 3.5 —

Intl 948 885 7.2 5.3 1.9

WW 2,418 2,305 4.9 4.2 0.7

HIPS

US 283 271 4.6 4.6 —

Intl 158 150 5.5 3.0 2.5

WW 441 421 4.9 4.0 0.9

KNEES

US 228 226 1.1 1.1 —

Intl 182 164 11.4 10.3 1.1

WW 410 389 5.5 5.0 0.5

TRAUMA

US 536 501 6.7 6.7 —

Intl 291 267 9.2 7.4 1.8

WW 827 768 7.6 6.9 0.7

SPINE, SPORTS & OTHER

US 423 422 0.2 0.2 —

Intl 317 305 4.0 1.9 2.1

WW 740 727 1.8 0.9 0.9

TOTAL MEDTECH

US 4,554 4,383 3.9 3.9 —

Intl 4,372 4,158 5.2 3.2 2.0

WW $8,926 8,541 4.5 % 3.6 % 0.9 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SIX MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)

ONCOLOGY

US $7,684 6,398 20.1 % 20.1 % — %

Intl 6,695 5,592 19.7 13.2 6.5

WW 14,379 11,990 19.9 16.9 3.0

DARZALEX

US 4,643 3,846 20.7 20.7 —

Intl 3,528 2,930 20.4 13.7 6.7

WW 8,171 6,776 20.6 17.7 2.9

CARVYKTI

US 905 676 33.8 33.8 —

Intl 349 132 * * *

WW 1,254 808 55.1 52.1 3.0

TECVAYLI

US 313 219 43.1 43.1 —

Intl 148 98 51.1 45.2 5.9

WW 462 317 45.5 43.7 1.8

TALVEY

US 213 150 41.7 41.7 —

Intl 113 42 * * *

WW 326 192 69.3 67.2 2.1

RYBREVANT / LAZCLUZE

US 365 252 45.0 45.0 —

Intl 181 69 * * *

WW 546 320 70.4 69.9 0.5

ERLEADA

US 738 670 10.2 10.2 —

Intl 1,206 1,009 19.4 12.5 6.9

WW 1,944 1,679 15.8 11.6 4.2

IMBRUVICA

US 292 474 (38.4) (38.4) —

Intl 966 970 (0.4) (6.7) 6.3

WW 1,259 1,444 (12.9) (17.1) 4.2

OTHER ONCOLOGY(3)

US 216 110 94.5 94.5 —

Intl 203 341 (40.5) (41.3) 0.8

WW 418 452 (7.4) (8.0) 0.6

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SIX MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

IMMUNOLOGY

US $4,227 4,701 (10.1) % (10.1) % — %

Intl 2,997 2,999 (0.1) (5.0) 4.9

WW 7,224 7,700 (6.2) (8.1) 1.9

TREMFYA

US 2,507 1,395 79.7 79.7 —

Intl 1,147 747 53.6 45.5 8.1

WW 3,654 2,142 70.6 67.8 2.8

SIMPONI / SIMPONI ARIA

US 529 597 (11.2) (11.2) —

Intl 736 753 (2.3) (6.9) 4.6

WW 1,265 1,349 (6.2) (8.8) 2.6

REMICADE

US 484 597 (19.0) (19.0) —

US Exports(4)

28 44 (37.1) (37.1) —

Intl 248 281 (11.5) (15.4) 3.9

WW 760 922 (17.6) (18.7) 1.1

STELARA

US 556 2,059 (73.0) (73.0) —

Intl 839 1,219 (31.1) (34.6) 3.5

WW 1,396 3,278 (57.4) (58.7) 1.3

OTHER IMMUNOLOGY

US 123 9 * * —

Intl 27 0 * * *

WW 150 9 * * *

NEUROSCIENCE

US 3,153 2,345 34.5 34.5 —

Intl 1,359 1,353 0.4 (3.7) 4.1

WW 4,512 3,698 22.0 20.5 1.5

SPRAVATO

US 920 642 43.4 43.4 —

Intl 131 93 41.8 31.9 9.9

WW 1,052 734 43.2 42.0 1.2

CAPLYTA(5)

US 631 211 * * —

Intl — — — — —

WW 631 211 * * —

INVEGA SUSTENNA / XEPLION / INVEGA

TRINZA / TREVICTA

US 1,496 1,357 10.2 10.2 —

Intl 558 537 3.7 (0.1) 3.8

WW 2,053 1,895 8.4 7.3 1.1

CONCERTA / methylphenidate

US 34 62 (45.5) (45.5) —

Intl 248 249 (0.4) (3.0) 2.6

WW 282 312 (9.5) (11.5) 2.0

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SIX MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

OTHER NEUROSCIENCE

US $ 72 73 (1.1) % (1.1) % — %

Intl 422 474 (10.9) (15.1) 4.2

WW 494 547 (9.6) (13.2) 3.6

PULMONARY HYPERTENSION (PH)

US 1,645 1,543 6.5 6.5 —

Intl 633 595 6.4 2.3 4.1

WW 2,278 2,138 6.5 5.4 1.1

UPTRAVI

US 771 747 3.2 3.2 —

Intl 206 180 14.7 7.7 7.0

WW 977 927 5.4 4.0 1.4

OPSUMIT / OPSYNVI

US 849 766 10.9 10.9 —

Intl 359 339 6.1 2.7 3.4

WW 1,208 1,104 9.4 8.4 1.0

OTHER PULMONARY HYPERTENSION

US 25 31 (19.0) (19.0) —

Intl 68 77 (11.5) (12.3) 0.8

WW 93 107 (13.6) (14.2) 0.6

INFECTIOUS DISEASES (ID)

US 642 635 1.1 1.1 —

Intl 1,010 971 4.1 (2.5) 6.6

WW 1,652 1,605 2.9 (1.1) 4.0

EDURANT / rilpivirine

US 10 14 (29.3) (29.3) —

Intl 749 704 6.4 (0.3) 6.7

WW 759 718 5.7 (0.9) 6.6

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US 630 617 2.1 2.1 —

Intl 185 183 1.2 (5.6) 6.8

WW 815 799 1.9 0.4 1.5

OTHER INFECTIOUS DISEASES

US 2 4 (51.6) (51.6) —

Intl 76 84 (9.0) (13.7) 4.7

WW 78 88 (11.1) (15.5) 4.4

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SIX MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CARDIOVASCULAR / METABOLISM / OTHER (CVM)

US $ 1,499 1,631 (8.1) % (8.1) % — %

Intl 266 312 (14.8) (19.5) 4.7

WW 1,765 1,943 (9.2) (9.9) 0.7

XARELTO

US 1,306 1,311 (0.3) (0.3) —

Intl — — — — —

WW 1,306 1,311 (0.3) (0.3) —

OTHER

US 192 320 (39.9) (39.9) —

Intl 266 312 (14.8) (19.5) 4.7

WW 458 632 (27.5) (29.8) 2.3

TOTAL PH, ID, CVM

US 3,785 3,809 (0.6) (0.6) —

Intl 1,909 1,878 1.7 (3.8) 5.5

WW 5,694 5,686 0.1 (1.7) 1.8

TOTAL INNOVATIVE MEDICINE

US 18,850 17,253 9.3 9.3 —

Intl 12,960 11,822 9.6 3.9 5.7

WW $ 31,810 29,075 9.4 % 7.1 % 2.3 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SIX MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)

CARDIOVASCULAR

US $ 2,825 2,625 7.6 % 7.6 % — %

Intl 1,956 1,790 9.3 5.2 4.1

WW 4,781 4,416 8.3 6.6 1.7

ELECTROPHYSIOLOGY

US 1,519 1,425 6.6 6.6 —

Intl 1,502 1,366 10.0 5.6 4.4

WW 3,022 2,791 8.3 6.2 2.1

ABIOMED

US 731 699 4.6 4.6 —

Intl 197 170 16.1 11.4 4.7

WW 928 868 6.8 5.9 0.9

SHOCKWAVE

US 510 439 16.1 16.1 —

Intl 130 110 17.7 17.2 0.5

WW 640 550 16.4 16.3 0.1

OTHER CARDIOVASCULAR

US 65 63 3.1 3.1 —

Intl 127 144 (11.9) (15.3) 3.4

WW 192 207 (7.4) (9.7) 2.3

SURGERY

US 2,140 2,045 4.7 4.7 —

Intl 3,024 2,906 4.1 (0.3) 4.4

WW 5,164 4,951 4.3 1.8 2.5

ADVANCED

US 976 934 4.5 4.5 —

Intl 1,337 1,303 2.6 (1.4) 4.0

WW 2,312 2,237 3.4 1.0 2.4

GENERAL

US 1,165 1,111 4.8 4.8 —

Intl 1,687 1,603 5.2 0.7 4.5

WW 2,852 2,714 5.1 2.4 2.7

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

SIX MONTHS

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)(Continued)

VISION

US $1,144 1,123 1.9 % 1.9 % — %

Intl 1,672 1,526 9.6 6.7 2.9

WW 2,816 2,648 6.3 4.6 1.7

CONTACT LENSES / OTHER

US 913 881 3.7 3.7 —

Intl 1,081 1,003 7.7 5.0 2.7

WW 1,994 1,884 5.8 4.4 1.4

SURGICAL

US 231 242 (4.5) (4.5) —

Intl 591 523 13.1 9.8 3.3

WW 822 764 7.5 5.3 2.2

ORTHOPAEDICS

US 2,905 2,804 3.6 3.6 —

Intl 1,896 1,742 8.9 3.9 5.0

WW 4,801 4,546 5.6 3.7 1.9

HIPS

US 560 534 4.9 4.9 —

Intl 317 296 7.2 1.7 5.5

WW 877 830 5.7 3.8 1.9

KNEES

US 467 457 2.2 2.2 —

Intl 363 322 13.0 8.4 4.6

WW 830 778 6.7 4.8 1.9

TRAUMA

US 1,068 1,003 6.4 6.4 —

Intl 592 537 10.3 5.2 5.1

WW 1,660 1,540 7.8 6.0 1.8

SPINE, SPORTS & OTHER

US 810 810 0.0 0.0 —

Intl 624 588 6.1 1.3 4.8

WW 1,434 1,398 2.6 0.6 2.0

TOTAL MEDTECH

US 9,013 8,596 4.8 4.8 —

Intl 8,549 7,965 7.3 3.2 4.1

WW $17,562 16,561 6.0 % 4.1 % 1.9 %

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1)Operational growth excludes the effect of translational currency

(2)Unaudited

(3)Includes the sales of ZYTIGA which were previously disclosed separately

(4)Reported as U.S. sales

(5)Acquired with Intra-Cellular Therapies on April 2, 2025

GRAPHIC

Filename: image_1.jpg · Sequence: 8

Binary file (339 bytes)

Download image_1.jpg

GRAPHIC

Filename: jnjlogo.jpg · Sequence: 9

Binary file (2962 bytes)

Download jnjlogo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Jul. 15, 2026

Cover [Abstract]

Document Period End Date

Jul. 15, 2026

Document Type

8-K

Entity Registrant Name

Johnson & Johnson

Entity Incorporation, State or Country Code

Entity File Number

1-3215

Entity Tax Identification Number

22-1024240

Entity Address, Address Line One

One Johnson & Johnson Plaza

Entity Address, City or Town

New Brunswick

Entity Address, State or Province

Entity Address, Postal Zip Code

08933

City Area Code

732

Local Phone Number

524-0400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Document Information [Line Items]

Entity Emerging Growth Company

false

Entity Central Index Key

0000200406

Amendment Flag

false

Common Stock

Cover [Abstract]

Title of 12(b) Security

Common Stock, Par Value $1.00

Document Information [Line Items]

Title of 12(b) Security

Common Stock, Par Value $1.00

Trading Symbol

JNJ

Security Exchange Name

NYSE

Trading Symbol

JNJ

Security Exchange Name

NYSE

1.150% Notes Due November 2028

Cover [Abstract]

Title of 12(b) Security

1.150% Notes Due November 2028

Document Information [Line Items]

Title of 12(b) Security

1.150% Notes Due November 2028

Trading Symbol

JNJ28

Security Exchange Name

NYSE

Trading Symbol

JNJ28

Security Exchange Name

NYSE

1.650% Notes Due 2035

Cover [Abstract]

Title of 12(b) Security

1.650% Notes Due May 2035

Document Information [Line Items]

Title of 12(b) Security

1.650% Notes Due May 2035

Trading Symbol

JNJ35

Security Exchange Name

NYSE

Trading Symbol

JNJ35

Security Exchange Name

NYSE

3.20% Notes Due June 2032

Cover [Abstract]

Title of 12(b) Security

3.200% Notes Due June 2032

Document Information [Line Items]

Title of 12(b) Security

3.200% Notes Due June 2032

Trading Symbol

JNJ32

Security Exchange Name

NYSE

Trading Symbol

JNJ32

Security Exchange Name

NYSE

3.350% Notes Due June 2036

Cover [Abstract]

Title of 12(b) Security

3.350% Notes Due June 2036

Document Information [Line Items]

Title of 12(b) Security

3.350% Notes Due June 2036

Trading Symbol

JNJ36A

Security Exchange Name

NYSE

Trading Symbol

JNJ36A

Security Exchange Name

NYSE

3.550% Notes Due June 2044

Cover [Abstract]

Title of 12(b) Security

3.550% Notes Due June 2044

Document Information [Line Items]

Title of 12(b) Security

3.550% Notes Due June 2044

Trading Symbol

JNJ44

Security Exchange Name

NYSE

Trading Symbol

JNJ44

Security Exchange Name

NYSE

2.700% Notes due February 2029

Cover [Abstract]

Title of 12(b) Security

2.700% Notes due February 2029

Document Information [Line Items]

Title of 12(b) Security

2.700% Notes due February 2029

Trading Symbol

JNJ29B

Security Exchange Name

NYSE

Trading Symbol

JNJ29B

Security Exchange Name

NYSE

3.050% Notes due February 2033

Cover [Abstract]

Title of 12(b) Security

3.050% Notes due February 2033

Document Information [Line Items]

Title of 12(b) Security

3.050% Notes due February 2033

Trading Symbol

JNJ33B

Security Exchange Name

NYSE

Trading Symbol

JNJ33B

Security Exchange Name

NYSE

3.350% Notes due February 2037

Cover [Abstract]

Title of 12(b) Security

3.350% Notes due February 2037

Document Information [Line Items]

Title of 12(b) Security

3.350% Notes due February 2037

Trading Symbol

JNJ37B

Security Exchange Name

NYSE

Trading Symbol

JNJ37B

Security Exchange Name

NYSE

3.600% Notes due February 2045

Cover [Abstract]

Title of 12(b) Security

3.600% Notes due February 2045

Document Information [Line Items]

Title of 12(b) Security

3.600% Notes due February 2045

Trading Symbol

JNJ45

Security Exchange Name

NYSE

Trading Symbol

JNJ45

Security Exchange Name

NYSE

3.700% Notes due February 2055

Cover [Abstract]

Title of 12(b) Security

3.700% Notes due February 2055

Document Information [Line Items]

Title of 12(b) Security

3.700% Notes due February 2055

Trading Symbol

JNJ55

Security Exchange Name

NYSE

Trading Symbol

JNJ55

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDueMay2035Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueJune2032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueJune2036Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueJune2044Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A2.700NotesDueFebruary2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.050NotesDueFebruary2033Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueFebruary2037Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.600NotesDueFebruary2045Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.700NotesDueFebruary2055Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: